The role of P2Y₁₂ receptor and activated platelets during inflammation
- PMID: 24845219
- PMCID: PMC5681251
- DOI: 10.2174/1389450115666140519162133
The role of P2Y₁₂ receptor and activated platelets during inflammation
Abstract
Platelets play an important role not only during thrombosis, but also in modulating immune responses through their interaction with immune cells and by releasing inflammatory mediators upon activation. The P2Y12 receptor is a Gi-coupled receptor that not only regulates ADP-induced aggregation but can also dramatically potentiate secretion, when platelets are activated by other stimuli. Considering the importance of P2Y12 receptor in platelet function, a class of antiplatelet drugs, thienopyridines, have been designed and successfully used to prevent thrombosis. This review will focus on the role of activated platelets in inflammation and the effects that P2Y12 antagonism exerts on the inflammatory process. A change in platelet functions was noted in patients treated with thienopyridines during inflammatory conditions, suggesting that platelets may modulate the inflammatory response. Further experiments in a variety of animal models of diseases, such as sepsis, rheumatoid arthritis, myocardial infarction, pancreatitis and pulmonary inflammation have also demonstrated that activated platelets influence the inflammatory state. Platelets can secrete inflammatory modulators in a P2Y12-dependent manner, and, as a result, directly alter the inflammatory response. P2Y12 receptor may also be expressed in other cells of the immune system, indicating that thienopyridines could directly influence the immune system rather than only through platelets. Overall the results obtained to date strongly support the notion that activated platelets significantly contribute to the inflammatory process and that antagonizing P2Y12 receptor can influence the immune response.
Conflict of interest statement
The author(s) confirm that this article content has no conflicts of interest.
Similar articles
-
Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.Br J Pharmacol. 2016 Apr;173(7):1163-78. doi: 10.1111/bph.13429. Epub 2016 Feb 24. Br J Pharmacol. 2016. PMID: 26758983 Free PMC article. Review.
-
Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.Thromb Haemost. 2015 Aug 31;114(3):478-89. doi: 10.1160/TH14-11-0943. Epub 2015 Apr 23. Thromb Haemost. 2015. PMID: 25904241 Review.
-
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.Thromb Haemost. 2018 Feb;118(2):362-368. doi: 10.1160/TH17-07-0466. Epub 2018 Jan 29. Thromb Haemost. 2018. PMID: 29443372 Clinical Trial.
-
The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges.Int J Mol Sci. 2023 Apr 4;24(7):6709. doi: 10.3390/ijms24076709. Int J Mol Sci. 2023. PMID: 37047682 Free PMC article. Review.
-
Effect of P2Y12 inhibitors on inflammation and immunity.Thromb Haemost. 2015 Aug 31;114(3):490-7. doi: 10.1160/TH14-12-1068. Epub 2015 Jul 9. Thromb Haemost. 2015. PMID: 26156883 Review.
Cited by
-
Physical Aggression and Coronary Artery Calcification: A North Texas Healthy Heart Study.Int J Behav Med. 2022 Feb;29(1):14-24. doi: 10.1007/s12529-021-09989-7. Epub 2021 Apr 20. Int J Behav Med. 2022. PMID: 33880713
-
MAVS signaling shapes microglia responses to neurotropic virus infection.J Neuroinflammation. 2024 Oct 18;21(1):264. doi: 10.1186/s12974-024-03258-6. J Neuroinflammation. 2024. PMID: 39425188 Free PMC article.
-
Role and recent progress of P2Y12 receptor in cancer development.Purinergic Signal. 2024 Jun 14. doi: 10.1007/s11302-024-10027-w. Online ahead of print. Purinergic Signal. 2024. PMID: 38874752 Review.
-
Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis.Mol Biol Rep. 2023 May;50(5):4675-4686. doi: 10.1007/s11033-023-08322-7. Epub 2023 Apr 6. Mol Biol Rep. 2023. PMID: 37022526 Free PMC article. Review.
-
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.Circulation. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928. Epub 2020 Jun 27. Circulation. 2020. PMID: 32795098 Free PMC article. Clinical Trial.
References
-
- Italiano JE, Jr, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost. 2003;1(6):1174–82. - PubMed
-
- Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost. 2003;1(7):1602–12. - PubMed
-
- Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227–34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources